{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T20:49:09Z","timestamp":1788468549840,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"\n Aims<\/jats:title>\n Due to its high heterogenicity and unclear etiology, there is currently no specific treatment for polycystic ovary syndrome (PCOS). Metformin, as an insulin sensitizer, combined with spironolactone, an antiandrogen medication, may exert complementary effects on PCOS. We therefore performed a meta-analysis of trials in which metformin combined with spironolactone was applied to treat PCOS to evaluate the efficacy and safety of the combination therapy.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We retrieved the PubMed, Embase, Scopus, Cochrane Library, CNKI, CBM, Wangfang, and VIP databases for literatures published from their inception to December 16, 2022 on the effects of metformin combined with spironolactone in the treatment of PCOS. Inclusion criteria according to P.I.C.O.S criteria were: PCOS patients, metformin combined with spironolactone interventions, metformin alone control group, and randomized controlled trials with the following outcome data: body mass index (BMI), hirsutism score, luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone (TT), fasting blood glucose (FBG), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), and side effects including nausea, vomiting, diarrhea and drug withdrawal.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Our results revealed that metformin combined with spironolactone significantly reduced BMI and TT, but that it exerted no significant effects on hirsutism score, or on FSH or LH concentrations. Combined treatment also resulted in a significant diminution in FBG and insulin resistance using the HOMA-IR when the interventional time was greater than 6 months. In addition, the combination did not have a higher occurrence of adverse reactions than metformin alone.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Compared with metformin alone, metformin combined with spironolactone therapy may be more effective in reducing BMI and serum androgen levels, but the combination showed no significant effect on the hirsutism score or gonadotropin hormone levels, and was not associated with an elevation in side-effects. Moreover, when the treatment course was greater than 6 months, combination therapy reduced FBG and improved insulin resistance more effectively than metformin alone. However, more research is needed to determine the most effective course of treatment.<\/jats:p>\n <\/jats:sec>\n \n Systematic review registration<\/jats:title>\n \n https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:uri>\n , identifier CRD42022355515.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fendo.2023.1223768","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T20:57:52Z","timestamp":1691701072000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Metformin combined with spironolactone vs. metformin alone in polycystic ovary syndrome: a meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Huamin","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenrui","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingru","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leneng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.fertnstert.2016.05.003","article-title":"Criteria, prevalence, and phenotypes of polycystic ovary syndrome","volume":"106","author":"Lizneva","year":"2016","journal-title":"Fertility Sterility"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14421","article-title":"Obesity and polycystic ovary syndrome","volume":"95","author":"Barber","year":"2021","journal-title":"Clin Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1210\/er.2015-1018","article-title":"Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome","volume":"36","author":"Dumesic","year":"2015","journal-title":"Endocr Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2018.04.008","article-title":"Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy","author":"Patel","year":"2018","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.198916","article-title":"Increased risk of psychiatric disorders in women with polycystic ovary syndrome in southwest China","volume":"130","author":"Tan","year":"2017","journal-title":"Chin Med J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1692-3","article-title":"Psychiatric disorders in women with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"62","author":"Brutocao","year":"2018","journal-title":"Endocrine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2018.24","article-title":"Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment","volume":"14","author":"Escobar-Morreale","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2014.09.018","article-title":"Metformin: from mechanisms of action to therapies","volume":"20","author":"Foretz","year":"2014","journal-title":"Cell Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.3805","article-title":"Metformin in 2019","volume":"321","author":"Flory","year":"2019","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2350","article-title":"Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline","volume":"98","author":"Legro","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2018.05.004","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"110","author":"Teede","year":"2018","journal-title":"Fertil Steril"},{"key":"B12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/9780470712184.ch8","article-title":"Assessing risk of bias in included studies","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2008"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4103\/mmj.mmj_61_19","article-title":"Effects of metformin alone and in combination with spironolactone on hyperandrogenism in polycystic ovarian syndrome","volume":"33","author":"Nasser","year":"2020","journal-title":"Menoufia Med J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2013.04.016","article-title":"In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone","volume":"24","author":"Mazza","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9927240","article-title":"Effects of low-dose spironolactone combined with metformin or either drug alone on insulin resistance in patients with polycystic ovary syndrome: A pilot study","volume":"2022","author":"Long","year":"2022","journal-title":"Int J Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1040","article-title":"Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study","volume":"98","author":"Ganie","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","article-title":"Combination treatment with metformin and spironolactone in patients with polycystic ovary syndrome","volume-title":"Clinical Focus","author":"Zhao","year":"2016"},{"key":"B18","article-title":"Clinical study of metformin combined with spironolactone for Polycystic Ovary Syndrome","volume-title":"Journal of Contemporary Clinical Medicine","author":"Che","year":"2016"},{"key":"B19","doi-asserted-by":"publisher","first-page":"E1230","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis Campbell Systematic Reviews","volume":"18","author":"Haddaway","year":"2022"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-020-05951-2","article-title":"Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update","volume":"303","author":"Abraham Gnanadass","year":"2021","journal-title":"Arch Gynecol Obstet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116940","article-title":"Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome","volume":"236","author":"Wang","year":"2019","journal-title":"Life Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2016.12.320","article-title":"Spironolactone","volume":"53","author":"Carone","year":"2017","journal-title":"J Pain Symptom Manage"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2009.09.005","article-title":"PCOS in adolescents","volume":"24","author":"Diamanti-Kandarakis","year":"2010","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.cbi.2019.108742","article-title":"Very low dose spironolactone protects experimentally-induced polycystic ovarian syndrome from insulin-resistant metabolic disturbances by suppressing elevated circulating testosterone","author":"Adeyanju","year":"2019","journal-title":"Chemico-Biological Interact"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/jci115274","article-title":"INSULIN RESISTANCE ASSOCIATED WITH LOWER RATES OF WEIGHT-GAIN IN PIMA-INDIANS","volume":"88","author":"Swinburn","year":"1991","journal-title":"J Clin Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2020.110939","article-title":"Genetic and environmental associations between insulin resistance and weight-related traits and future weight change","author":"Song","year":"2020","journal-title":"Nutrition"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2986.","article-title":"Ten-year weight gain is associated with elevated fasting insulin levels and precedes glucose elevation","volume":"34","author":"Pennings","year":"2018","journal-title":"Diabetes-Metabolism Res Rev"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab415","article-title":"Relationship between insulin sensitivity and menstrual cycle is modified by BMI, fitness, and physical activity in NHANES","volume":"106","author":"MacGregor","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3978\/j.issn.2305-5839.2014.04.15","article-title":"Metformin use in women with polycystic ovary syndrome","volume":"2","author":"Johnson","year":"2014","journal-title":"Ann Transl Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01739","article-title":"The efficacy of 24-month metformin for improving menses, hormones, and metabolic profiles in polycystic ovary syndrome","volume":"103","author":"Yang","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-2339.","article-title":"Defining insulin resistance from hyperinsulinemic-euglycemic clamps","volume":"35","author":"Tam","year":"2012","journal-title":"Diabetes Care"},{"key":"B32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12902-022-01143-y","article-title":"Low-dose spironolactone ameliorates adipose tissue inflammation and apoptosis in letrozole-induced PCOS rat model","volume":"22","author":"Areloegbe","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2021.108907","article-title":"Association between biochemical hyperandrogenism parameters and modified Ferriman-Gallwey score in patients with hirsutism in Basrah (Southern Iraq)","volume":"38","author":"Hussein","year":"2021","journal-title":"Postepy Dermatol Alergol"},{"key":"B34","article-title":"Dose comparison and side effect profile of metformin extended release versus metformin immediate release","volume":"29","author":"Hameed","year":"2017","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084110.","article-title":"Controversies in the pathogenesis, diagnosis and treatment of PCOS: focus on insulin resistance, inflammation, and hyperandrogenism","volume":"23","author":"Armanini","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/s1472-6483(10)61100-5","article-title":"Medical treatment regimens of hirsutism","volume":"8","author":"Sahin","year":"2004","journal-title":"Reprod BioMed Online"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1223768\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T20:58:04Z","timestamp":1691701084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1223768\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":36,"alternative-id":["10.3389\/fendo.2023.1223768"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1223768","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]},"article-number":"1223768"}}